Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on liver-directed cancer therapies, today announced the presentation of new subgroup analysis data from the FOCUS Phase ...

And then at ESMO, of course, we have the plenary presentation ... cystectomy is a very difficult procedure. Sounds quite horrible. How real world is this trial then? You said, I mean, 85% of ...

Given as neoadjuvant treatment, TAR-200 plus cetrelimab generated responses in patients with muscle-invasive bladder cancer.

ORRs of 54.8% and 50.0% achieved in locally advanced and metastatic cSCC, with median follow-up durations of 24.1 and 29.3 months, respectively. Results demonstrate a deepening of response over time, ...

A new GALAXY study reveals Signatera's cell-free DNA test predicts survival rates and chemotherapy benefits for colorectal ...

The critical need to improve prior authorisation processes might have reached its tipping point on the 17th January. That’s ...

Patients with muscle-invasive bladder cancer who were treated with presurgical chemotherapy may have a 55% lower risk of ...

Imfinzi and chemotherapy before surgery, followed by Imfinzi after surgery, generated survival benefits in cisplatin-eligible ...

GlyTherix Ltd (GlyTherix) an Australian targeted radiotherapy company specializing in developing antibody ...

The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the sprawling Fira Gran Via centre in Barcelona.